WO2020233589A1 - 靶向cd19的全人源抗体及其应用 - Google Patents

靶向cd19的全人源抗体及其应用 Download PDF

Info

Publication number
WO2020233589A1
WO2020233589A1 PCT/CN2020/091235 CN2020091235W WO2020233589A1 WO 2020233589 A1 WO2020233589 A1 WO 2020233589A1 CN 2020091235 W CN2020091235 W CN 2020091235W WO 2020233589 A1 WO2020233589 A1 WO 2020233589A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
antibody
cells
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/091235
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
WO2020233589A9 (zh
Inventor
谭涛超
戴振宇
贾向印
魏巧娥
杨永坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Iaso Biotherapeutics Co Ltd
Original Assignee
Nanjing Iaso Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3141498A priority Critical patent/CA3141498C/en
Priority to EP20809306.2A priority patent/EP3974452A4/en
Priority to AU2020277525A priority patent/AU2020277525A1/en
Priority to CN202310120560.XA priority patent/CN116589579A/zh
Priority to JP2022516254A priority patent/JP7566352B2/ja
Priority to US17/613,367 priority patent/US12516117B2/en
Application filed by Nanjing Iaso Biotherapeutics Co Ltd filed Critical Nanjing Iaso Biotherapeutics Co Ltd
Priority to CN202080037449.9A priority patent/CN113840841B/zh
Publication of WO2020233589A1 publication Critical patent/WO2020233589A1/zh
Publication of WO2020233589A9 publication Critical patent/WO2020233589A9/zh
Anticipated expiration legal-status Critical
Priority to US19/418,243 priority patent/US20260103517A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the present invention relates to a fully human antibody targeting CD19, and also relates to a chimeric antigen receptor (CAR) comprising a single chain antibody (scFv) of the fully human antibody.
  • CAR chimeric antigen receptor
  • the fully human antibody and its scFv and CAR can be used for the construction of CAR-T cells targeting CD19.
  • Kymriah is the world's first approved CAR-T treatment product for the treatment of acute lymphoblastic leukemia patients aged 3 to 25 and adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • Yescarta is the second CAR-T product approved for marketing in the world, used to treat adult relapsed or refractory B-cell lymphoma and non-Hodgkin's lymphoma.
  • Figure 1 shows the schematic molecular structure of commonly used CARs.
  • CAR-T technology has completely different treatment principles from traditional treatment methods such as surgery, chemotherapy, and radiotherapy, and has a revolutionary therapeutic effect on refractory and relapsed hematological tumor diseases, it has opened up a new era of tumor treatment.
  • CAR-T clinical trials have been carried out all over the world, and China and the United States are the countries with the most relevant clinical trials.
  • CD19 is indicated for B lymphocyte tumors. Because of its definite curative effect and controllable side effects, it is the most among the products currently on the market and under research. With the deepening of clinical research, more and more evidence shows that the short-term effect of CD19 CAR-T treatment is very good, but as time goes by, about 50% of patients will relapse. There are many reasons for recurrence, mainly divided into CD19 antigen-negative recurrence and positive recurrence. In the CD19 antigen-positive recurrence, the short duration of CAR-T cells in the patient's body is the main reason.
  • ADA anti-antibody
  • CTL killer T lymphocytes
  • a fully human antibody or single chain antibody or fragment thereof targeting CD19 wherein the light chain variable region of the fully human antibody includes LCDR1, LCDR2, and LCDR3, and the heavy chain variable region includes HCDR1 , HCDR2 and HCDR3, wherein said LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 are selected from one of the following combinations:
  • LCDR1 amino acid sequence of LCDR1 is SSNIGAGYD;
  • the amino acid sequence of LCDR2 is ENT
  • the amino acid sequence of LCDR3 is QSYDSSLSGWRV;
  • HCDR1 The amino acid sequence of HCDR1 is GYSFTNSW;
  • HCDR2 The amino acid sequence of HCDR2 is IYPDDSDT;
  • amino acid sequence of HCDR3 is ARQSTYIYGGYYDT
  • the amino acid sequence of LCDR2 is YDD
  • the amino acid sequence of LCDR3 is AAWDDSLNGWV;
  • HCDR1 The amino acid sequence of HCDR1 is GYSFTSYW;
  • amino acid sequence of HCDR2 is IYPGDSDT
  • the amino acid sequence of HCDR3 is ARLSYSWSSWYWDF.
  • the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 8 and the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 9; or the light chain may The variable region includes the amino acid sequence shown in SEQ ID NO: 11, and the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 12.
  • the single-chain antibody includes the amino acid sequence shown in SEQ ID NO: 7 or 10.
  • a chimeric antigen receptor targeting CD19 which includes a CD19-targeting single-chain antibody whose light chain variable region includes LCDR1, LCDR2, and LCDR3, and a heavy chain variable region Including HCDR1, HCDR2 and HCDR3, wherein said LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 are selected from one of the following combinations:
  • LCDR1 amino acid sequence of LCDR1 is SSNIGAGYD;
  • the amino acid sequence of LCDR2 is ENT
  • the amino acid sequence of LCDR3 is QSYDSSLSGWRV;
  • HCDR1 The amino acid sequence of HCDR1 is GYSFTNSW;
  • HCDR2 The amino acid sequence of HCDR2 is IYPDDSDT;
  • amino acid sequence of HCDR3 is ARQSTYIYGGYYDT
  • the amino acid sequence of LCDR2 is YDD
  • the amino acid sequence of LCDR3 is AAWDDSLNGWV;
  • HCDR1 The amino acid sequence of HCDR1 is GYSFTSYW;
  • amino acid sequence of HCDR2 is IYPGDSDT
  • the amino acid sequence of HCDR3 is ARLSYSWSSWYWDF.
  • the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 8, and the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 9; or the light chain may The variable region includes the amino acid sequence shown in SEQ ID NO: 11, and the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 12. .
  • the single-chain antibody includes the amino acid sequence shown in SEQ ID NO: 7 or 10.
  • a modified T cell that expresses the aforementioned chimeric antigen receptor.
  • this document provides drugs for treating tumors expressing CD19 on the cell surface, which include the above-mentioned T cells.
  • nucleic acid molecule that encodes the aforementioned fully human antibody or single chain antibody or fragment thereof.
  • the sequence encoding the light chain variable region of the fully human antibody includes the nucleotide sequence shown in SEQ ID NO: 2, and the sequence encoding the heavy chain variable region includes the sequence shown in SEQ ID NO: 3.
  • the sequence encoding the light chain variable region of the human antibody includes the nucleotide sequence shown in SEQ ID NO: 5, and the sequence encoding the heavy chain variable region includes SEQ ID NO: 6 The nucleotide sequence shown.
  • sequence encoding the single-chain antibody includes the nucleotide sequence shown in SEQ ID NO: 1 or 4.
  • an expression vector including the aforementioned nucleic acid molecule.
  • the expression vector further includes the coding sequence of epidermal growth factor receptor (EGFR) or truncated form of EGFR (tEGFR).
  • EGFR epidermal growth factor receptor
  • tEGFR truncated form of EGFR
  • the fully human antibodies provided herein have lower immunogenicity than murine antibodies or humanized murine antibodies, and have better potential for antibody drugs or CAR-T applications. Compared with CAR-T cells using murine antibodies, CAR-T cells constructed using the fully human antibodies provided herein have better compatibility with the human body, and are beneficial to their long-term proliferation and survival in the body.
  • FIG. 1 is a schematic diagram of the structure of a chimeric antigen receptor (CAR) expressed on the cell surface.
  • CAR includes an extracellular binding region for binding to a specific target antigen (such as CD19), which is usually in the form of a single chain antibody (scFv); a hinge region between the cell membrane and the extracellular binding region; a cytoplasmic domain for transfection Direct the binding signal of the extracellular binding zone and activate the cell.
  • a specific target antigen such as CD19
  • scFv single chain antibody
  • a cytoplasmic domain for transfection Direct the binding signal of the extracellular binding zone and activate the cell.
  • Figure 2 shows the general process of screening specific antibodies targeting CD19 from the phage antibody library of the present invention.
  • Figure 3 shows the flow cytometric analysis results of cell clones obtained by knocking out Raji cells using different sgRNAs.
  • Figure 4 shows the results of enzyme-linked immunosorbent assay (ELISA) of the selected phage monoclonal and target antigen and control antigen.
  • Control 1 is FMC-63 (humanized mouse anti-human CD19 phage antibody clone);
  • Control 2 is a non-CD19 binding scFv phage antibody clone.
  • Figure 5 shows the results of flow cytometry analysis of partial phage monoclonal binding to Raji and Raji-CD19ko cells.
  • Figure 6 shows the results of flow cytometry analysis (MFI value) of the binding of the selected phage monoclonal to a variety of different CD19 positive and negative cell lines.
  • Control 1 is FMC-63 (humanized mouse anti-human CD19 phage antibody clone);
  • Control 2 is a negative control phage antibody clone.
  • Figure 7 shows the results of competitive binding experiments between FMC-63 antibody and #62, #78, FMC-63 phage.
  • Figure 8 shows a schematic diagram of the experimental principle of the reporter gene method for screening CAR molecules.
  • Figure 9 shows the activation of CAR-T cells constructed by the reporter gene method by various target cells, and the results are expressed in terms of the chemiluminescence intensity produced by luciferase.
  • Figure 10 shows the expression of CD19 on the surface of five target cells used in the reporter gene method experiment.
  • Figure 11 shows the results of CD107a degranulation of CAR-T cells by different target cells.
  • Figure 12 shows the killing results of CAR-T cells on multiple target cells (Nalm-6, Reh, Jvm-2, Jeko-1, Bv173, K562-CD19, K562, Thp-1 and Skm-1).
  • Figure 13 shows the killing of Nalm-6, Reh, Skm-1, and Thp-1 cells by CAR-T cells after stimulating CAR-T twice with Raji cells treated with mitomycin.
  • Figure 14 is a schematic diagram of the process of determining the affinity of FMC-63, #62, and #78scFv to the CD19 antigen.
  • Figure 15 shows the dynamic binding curves and KD, kon, and kdis parameters of FMC-63, #62, #78scFv and CD19 antigen affinity determination.
  • FIG 16 shows the experimental results of the membrane proteome array (MPA) of antibody #78.
  • Antibodies refer to immunoglobulins secreted by plasma cells (effector B cells) and used by the body's immune system to neutralize foreign substances (polypeptides, viruses, bacteria, etc.). This foreign substance is correspondingly called an antigen.
  • the basic structure of an antibody molecule is a 4-mer composed of two identical heavy chains and two identical light chains. According to the conservative difference in amino acid sequence, the heavy chain and light chain are divided into the variable region (V) at the amino terminal and the constant region (C) at the carboxy terminal. The variable regions of a heavy chain and a light chain interact to form an antigen binding site (Fv).
  • variable region the composition and sequence of amino acid residues in certain regions are more changeable than other regions (framework regions, FR) in the variable region, called hypervariable regions (HVR), which are actually antibodies The key part that binds to the antigen. Because these hypervariable region sequences are complementary to antigenic determinants, they are also called complementarity-determining regions (CDR). Both heavy chain and light chain have three complementary determining regions, which are called HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, respectively.
  • CDR complementarity-determining regions
  • Single chain antibody single chain fragment variable, scFv
  • scFv single chain fragment variable
  • Murine antibodies are antibodies produced by mice against specific antigens, and usually refer to antibodies produced by mouse B lymphocytes. In most cases, the murine antibody is a monoclonal antibody produced by hybridoma cells.
  • the fully human antibody of the present invention is obtained by screening from a human phage antibody library, which reduces immunogenicity compared with murine antibodies, and is more conducive to human therapeutic use.
  • Chimeric antigen receptor also known as chimeric T cell receptor or chimeric immune receptor
  • the chimeric antigen receptor usually consists of an extracellular antigen binding domain, a transmembrane domain, and an intracellular signal domain.
  • the antigen-binding domain is a scFv sequence, which is responsible for recognizing and binding a specific antigen.
  • the intracellular signal domain usually includes an immunoreceptor tyrosine activation motif (ITAM), such as a signal transduction domain derived from a CD3 ⁇ molecule, which is responsible for activating immune effector cells and producing a killing effect.
  • ITAM immunoreceptor tyrosine activation motif
  • the chimeric antigen receptor can also include a signal peptide at the amino terminus which is responsible for the intracellular localization of the nascent protein, and a hinge region between the antigen binding domain and the transmembrane domain.
  • the intracellular signal domain may also include, for example, a costimulatory domain derived from a 4-1BB molecule.
  • CAR-T cells refer to T cells that express CAR, and are usually obtained by transducing T cells with an expression vector encoding CAR.
  • Commonly used expression vectors are viral vectors, such as lentiviral expression vectors.
  • Chimeric antigen receptor-modified T cells are not restricted by major histocompatibility complexes, and have specific targeted killing activity and the ability to continuously expand.
  • CD19 is a marker molecule on the surface of B lymphocytes and plays a role in regulating B cell activation and development. CD19 is not only expressed on normal B cells, but also on many malignant B cell tumors. This forms the basis for CAR-T targeting CD19 in the clinical treatment of B cell related tumors.
  • Bound monoclonal antibody were further identified with a variety of CD19 positive (Raji, JVM-2, K562-CD19) and negative cell lines (Raji-CD19ko, Jurkat, K562) by flow cytometric analysis (FACS), among which 2 clones ( #62 and #78) showed good specificity on multiple cell lines. These two clones (#62 and #78) were constructed into CAR-T format and subjected to in vitro functional experiments.
  • the phage antibody library can be contacted with cells expressing and not expressing the target antigen, respectively, and panning by binding conditions Select or identify specific antibodies.
  • a better way is to construct cells that knock out the gene encoding the target antigen. In this way, the difference between a pair of cells is mainly in this knock-out gene. This is an important application for cells in monoclonal antibody binding specificity identification and affinity panning.
  • CRISPR/Cas9 technology to knock out the CD19 gene on Raji cells with high expression of CD19, and obtained CD19-negative monoclonal Raji-CD19ko cells through monoclonal screening.
  • sgRNA1 to sgRNA6 design a variety of sgRNA sequences (sgRNA1 to sgRNA6), and conduct primer synthesis;
  • FACS detects the gene knockout efficiency of different sgRNAs, selects cell pools with higher knockout efficiency, and separates single clones by limiting dilution;
  • the CD19 knockout efficiency of cells corresponding to sgRNA5 is the highest, with 75.4% of CD19 knocked out. Therefore, we choose sgRNA5 electroporated cell pool for monoclonal screening.
  • the limiting dilution method was used to isolate single clones from the cell pool, and after the single clones were amplified, the CD19 expression of these clones was detected by FACS.
  • the results are shown in Table 2.
  • the CD19 expression of Raji-CD19ko-1, 11, and 14 clones is basically undetectable, and it can be considered as a single clone with successful knockout. These 3 clones were cultured and frozen. We used clone 1 in the subsequent study.
  • CD19 is an antigen normally expressed by B lymphocytes in the human body. For such antigens, the body will inactivate those B cells that can express CD19 antibodies through the mechanism of cloning and screening, resulting in a lack of such antigens in normal humans. Of high-affinity antibodies. Clone screening is the body's normal self-recognition and self-protection mechanism. However, the most commonly used form of phage antibody library is the natural library, which is constructed by directly cloning antibody genes in healthy human lymphocytes.
  • the semi-synthetic antibody library is composed of light chain and heavy chain FR1-FR3 from natural antibody sequence and artificially designed heavy chain CDR3, which can greatly increase the diversity of antibodies and improve the screening of high-affinity antibodies against normal antigens in the body (such as CD19) Opportunity.
  • BCMA-Fc was used as the negative panning protein
  • CD19-Fc was used as the positive panning protein to perform multiple rounds of panning to obtain a phage pool enriched with the target antibody clone.
  • the experimental steps are briefly described as follows:
  • the enriched phage pool can be used for subsequent monoclonal selection and ELISA/FACS identification.
  • the Raji-CD19ko cells prepared in Example 1 were used as negative panning cells, and Raji cells were used as positive panning cells to perform multiple rounds of panning to obtain a phage pool enriched with target antibody clones.
  • steps 1) to 5 usually 3 to 4 rounds of panning are required until the recovery rate of phage (the number of eluted phage/the number of input phage) has increased significantly.
  • the enriched phage pool can be used for the next step of monoclonal selection and ELISA/FACS identification.
  • Fully human phage antibody library including natural library and semi-synthetic library
  • Example 3 Using enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FACS) to screen from enriched phage pools Select specific clones
  • the phage pool enriched by the affinity panning step contains phage antibodies of various properties: specific clones, non-specific clones, and negative clones.
  • specific clones we need to isolate a single clone from it, package it into a monoclonal phage, and conduct a preliminary screening of a large number of clones by enzyme-linked immunoassay (ELISA), and select the clones that specifically bind to the CD19 protein.
  • ELISA-specific clones flow cytometry is used for further screening to determine whether they can bind to the natural CD19 molecules on the cell surface.
  • the specific single-chain antibody sequence can be determined by DNA sequencing.
  • step 7 Add 100 ⁇ L of the cultured phage supernatant of step 1) to the wells coated with target antigen and control antigen, and bind for 2 hours at room temperature;
  • Monoclonal cells were randomly selected from the enriched phage antibody pool and packaged into phage.
  • the binding of the monoclonal phage to CD19-hFc-Bio protein and BCMA-hFc-Bio protein was detected by phage ELISA to find CD19-specific phage antibody clones.
  • the ELISA results of some clones are shown in Figure 4.
  • Control1 is FMC-63 (humanized mouse anti-human CD19 phage antibody clone);
  • Control2 is a non-CD19 binding scFv phage antibody clone.
  • clones #1, 4, 62, and 78 bind well to the target antigen CD19 (CD19-hFc-Bio), and do not bind to the control antigen BCMA (BCMA-hFc-Bio) and Streptavidin , Good specificity.
  • the clones #58 and #59 do not bind to the target antigen CD19 (CD19-hFc-Bio), irrelevant antigen BCMA (BCMA-hFc-Bio) and Streptavidin, which are negative clones.
  • the clones #79 and #81 can bind to the target antigen CD19 (CD19-hFc-Bio), but can also bind to the control antigen BCMA (BCMA-hFc-Bio) and are non-specific clones.
  • the FACS preliminary screening results of some clones are shown in Figure 5.
  • the #62 clone indicated by the arrow does not bind Raji-CD19ko, but binds to Raji cells, which is a specific clone; the other clones are non-specific (both two types of cells bind) or negative clones (no two types of cells bind).
  • ELISA and FACS preliminary screening we obtained a total of 13 specific clones.
  • Example 4 Using multiple cell lines to identify monoclonal specificity by FACS
  • the antibody used for treatment must have very good target specificity, only bind to the target antigen, and not any unrelated antigen; on the other hand, the amino acid sequence of the same antigen on different cell lines will be different (Isomers or mutants) or binding ligands are not the same, we also need to investigate whether our antibodies can bind to various target protein-positive cells. In order to further analyze the specificity and universality of these monoclonals and find the best candidate clones, we further evaluated the specificity of the primary clones by flow cytometry.
  • the rest of the reagents are the same as the FACS preliminary screening.
  • Antibodies used for treatment must have very good target specificity.
  • flow cytometry to identify the multiple clones obtained in Example 3 on more cell lines. The results are shown in Table 5 and Figure 6.
  • Control 1 is FMC-63 (humanized mouse anti-human CD19 phage antibody clone);
  • Control 2 is a negative control phage antibody clone.
  • Clones #62 and #78 bind to all three CD19-positive cell lines, have high median fluorescence intensity (MFI), and do not bind to CD19-negative cell lines, have low MFI and good specificity.
  • MFI median fluorescence intensity
  • FMC63 is the most widely used anti-CD19 murine clone.
  • CAR-T therapy using this clone has obtained impressive clinical results, which may be related to the characteristics of the clone and the CD19 antigen-binding epitope.
  • the phage of the clone to be tested and the FMC63 antibody of different concentration gradients were mixed in advance and then combined with the positive target cell NALM6, by incubating the primary antibody mouse anti M13 antibody and the secondary antibody FITC horse anti mouse-IgG (H+L) After the antibody was tested, the FITC fluorescence intensity was determined to determine whether the FMC63 antibody had an effect on the binding of #62phage and #78 phage to the positive target cell NALM6, so as to determine whether the two clones have similar binding properties to the scFv derived from mouse FMC63.
  • Antibody gradient dilution According to the original concentration of FMC63 Ab and CD22 (clone: M971) antibody, dilute it to 400 ⁇ g/mL, and then dilute to 40 ⁇ g/mL, 4 ⁇ g/mL, 0.4 ⁇ g/mL, 0.04 ⁇ g/mL, 0.004 ⁇ g/mL, add 50 ⁇ L of antibody to each well.
  • Bacteriophage packaging and dilution as described above, KO7 infection and packaging of #62 phage, #78 phage and FMC63 phage, according to the original titer, were diluted to two concentrations of 4x10 10 pfu/mL and 2x10 10 pfu/mL, Add 50 ⁇ L of bacteriophage to each well and mix well with the antibody in advance.
  • FMC63Ab and CD22 (clone: M971) antibodies, independently expressed by IASO BIO
  • Example 4 In order to confirm whether these specific clones obtained in Example 4 can specifically recognize target cells and activate CAR-T cells after being constructed into CAR-T, we have developed an efficient CAR-T screening method, namely the reporter gene method.
  • the principle is as follows Shown in Figure 8.
  • the activation of CAR-T cells is achieved by CD3 ⁇ and costimulatory factors in the intracellular region of CAR molecules.
  • CD3 ⁇ can activate the NFAT signaling pathway in cells, which is a necessary condition for CAR-T cell activation. Therefore, the NFAT reporter gene method can be used to screen out CAR molecules that can activate the NFAT signaling pathway.
  • NFAT-ffLuc NFAT-ffLuc (ffLuc, firefly luciferase) reporter gene were used as reporter cells.
  • the CAR-encoding nucleic acid molecules are transiently expressed on the surface of reporter cells by plasmid electrotransformation.
  • the reporter cell expressing the CAR molecule is incubated with the target cell, the surface antigen of the target cell can specifically activate the CAR molecule, thereby activating the expression of the reporter gene.
  • the ability of CAR molecules to activate the NFAT signaling pathway can be evaluated.
  • the plasmid also includes a sequence encoding truncated EGFR (tEGFR), which can be used to mark cells that successfully express CAR when tEGFR is expressed on the cell surface.
  • tEGFR truncated EGFR
  • CMV-hRLuc internal reference plasmid blended with CAR-encoding nucleic acid molecules to calibrate the electroporation efficiency.
  • this reporter gene method Compared with the traditional method of packaging lentivirus and reinfecting T cells to prepare CAR-T to detect the function, this reporter gene method has simple steps and can quickly and efficiently evaluate the ability and specificity of candidate CAR molecules to recognize tumor cells.
  • Electrotransfer kit Celetrix, Cat. No. 1207;
  • Raji, JVM2 and REH are positive target cells expressing CD19 antigen, and they have different CD19 antigen expression density (as shown in Figure 9).
  • Raji-CD19ko and K562 serve as negative target cells and do not express CD19 antigen on their surface.
  • PXL092 is a positive reference CAR molecule encoding FMC63-bbz.
  • 57-1, 62-1, 69-1, 70-1 are the CAR molecules to be tested, and 62-1 is constructed using the phage 62 described above.
  • the background signal may come from the influence of the upstream promoter of the reporter gene, or it may be caused by the spontaneous activation of CAR molecules. Therefore, the higher the background signal, the greater the possibility of spontaneous activation of CAR molecules.
  • the reporter cell and the negative target cell are incubated together, if the CAR molecule does not bind non-specifically, the signal obtained should be the same as the Buffer group.
  • the CAR molecule will be specifically activated by the surface antigen of the positive target cell to generate a signal, and the signal intensity is related to the antigen density.
  • the figure shows that CAR molecule No.
  • CAR 62-1 has the ability to activate the NFAT signaling pathway similar to that of the control PXL092, and there is no obvious non-specific activation problem.
  • CAR molecules 57-1 and 69-1 can also activate the NFAT signaling pathway, but they are worse than PXL092.
  • CAR molecule No. 70-1 has a strong background activation signal, and its ability to be specific to positive target cells is weak.
  • CAR molecules with activating function on CAR-T cells obtained by preliminary screening by the reporter gene method described above needs further confirmation.
  • CD107a is a marker of intracellular microvesicles. When the granzyme-loaded microvesicles are fused with the cell membrane, CD107a on the cell membrane will increase. When monesin (purchased from BioLegend) is used to block its recovery , Can quantitatively reflect the strength of microvesicle release. When CAR-T is stimulated by the target antigen on the target cells, it will cause the release of granzyme, and the activation of T cells can be judged by the increase of CD107a by flow cytometry.
  • Alexa Fluor 488 anti-human EGFR BioLegend, Cat. No. 352908;
  • FITC-CD19 protein Acro Biosystems, Cat. No. CD9-HF251.
  • CAR-T cells were obtained by lentiviral transduction, and the CAR-T cells were cultured in vitro for 9-12 days and then subjected to CD107a degranulation experiment.
  • the CAR-T cells to be tested and target cells, monensin and CD107a antibody were incubated together for 3h, and the cell density of CAR-T cells and target cells were both 5 ⁇ 10 5 cells/mL. Then, after labeling the sample with CD8 antibody, EGFR antibody (or CD19-FITC protein), flow cytometry is performed.
  • luciferase When target cells are killed by CAR-T cells, luciferase will be released and quickly inactivated (the half-life of firefly luciferase is about 0.5h). If target cells are not killed or inhibited by CAR-T cells, more luciferase will be produced as target cells expand and luciferase continues to express. Therefore, the killing of target cells by CAR-T can be detected by the activity of luciferase.
  • RLU luciferase activity reading
  • the three sets of CAR-T cell samples (#62, #78 clones and CAR-T cells prepared by the control FMC63) can effectively kill positive target cells when the effective target ratio is 4:1. There was no obvious killing when T cells and positive target cells were incubated together. All CAR-T and T cell samples were not significantly killed when incubated with negative target cells. Therefore, the three sets of CAR-T samples can specifically kill CD19-positive target cells, and there is no non-specific killing of CD19-negative target cells.
  • the target cells (Raji) treated with mitomycin (Mitomycin) are mixed with CD19 CAR-T cells of different groups for 3 times of stimulation, then CAR-T cells and target cells are incubated and cultured to determine different scFv CAR-T Whether the killing ability of target cells changes after being stimulated repeatedly.
  • the three groups of CAR-T cell samples (#62, #78 clones and control FMC63) can effectively kill the positive target cells in a dose-dependent manner.
  • All CAR-T and T cell samples and negative target cells were not significantly killed when they were incubated together. Therefore, the three groups of CAR-T samples can specifically kill CD19-positive target cells after repeated stimulation of positive target cells, and there is no non-specific killing of CD19-negative target cells.
  • the affinity between CD19scFvs and antigen may have an important impact on the killing effect and survival time of CAR-T in patients.
  • ForteBio's Octet molecular interaction technology was used to determine it.
  • the biomembrane interference technology used in the Octet system is a label-free technology that provides high-throughput biomolecular interaction information in real time.
  • the instrument emits white light to the sensor surface and collects the reflected light.
  • the reflection spectrum of different frequencies is affected by the thickness of the optical film of the biosensor.
  • the reflected light of some frequencies forms constructive interference (blue), while others are destructive. Interference (red).
  • interferences are detected by the spectrometer and form an interference spectrum, which is displayed as the phase shift intensity (nm) of the interference spectrum. Therefore, once the number of molecules bound to the sensor surface increases or decreases, the spectrometer will detect the displacement of the interference spectrum in real time, and this displacement directly reflects the thickness of the biofilm on the sensor surface, from which the interaction of the biomolecules can be obtained. High-quality data to determine the kinetic parameters of the interaction between biomolecules (Kon, Kdis and KD), providing important information for the development process.
  • Affinity refers to the strength of the binding of a single molecule to its ligand. It is usually measured and reported by the equilibrium dissociation constant (KD).
  • KD equilibrium dissociation constant
  • the equilibrium dissociation constant can be used to evaluate and rank the strength of the interaction between two molecules.
  • the binding of an antibody to its antigen is a reversible process, and the rate of the binding reaction is proportional to the concentration of the reactant.
  • the smaller the KD value the greater the affinity of the antibody to its target.
  • FMC63, #62, and #78 can all bind to the CD19 antigen, and the affinity order is: FMC63>#78>#62.
  • Membrane Proteome Array is a cell-based high-throughput platform that can be used to identify targets for isolated antibodies and other ligands that bind to membrane proteins.
  • Membrane proteins account for about a quarter of all proteins encoded by the human genome, and are usually folded into a complex conformation structure that is difficult to retain outside the cell.
  • the key feature of MPA is that the membrane protein can be directly expressed and tested in the cell in its natural state, thereby maintaining its structural integrity and natural post-translational modification.
  • MPA utilizes the largest membrane protein library assembled to date, representing more than 5000 unique membrane proteins. Through the MPA platform, we conducted a #78 specific test to verify whether it will non-specifically bind to antigens other than CD19 and assess the risk of off-target effects.
  • MPA contains about 5000 different membrane protein clones, which account for more than 90% of the human membrane protein group. Each clone is overexpressed in HEK-293T cells containing a cDNA-containing plasmid, which is stored in a 384-well cell culture plate. Independent transfection in separate wells, 36h incubation time to ensure the expression of membrane protein.
  • each array plate includes positive and negative controls.
  • #78 antibody has no non-specific binding to most of the more than 5000 membrane proteins, but it can be observed that it has a high expression of SDC1, Frizzled 4, HTR5A HEK-293T The phenomenon of cell binding.
  • SDC1 Frizzled 4
  • HTR5A HTR5A HEK-293T
  • the phenomenon of cell binding In order to verify whether the binding is reproducible, we carried out a concentration gradient dilution of #78 antibody and repeated the experiment. The experimental results showed that #78 antibody can bind to HEK-293T cells with high expression of CD19 and positive control (ProteinA). And the average fluorescence intensity of its binding is dose-dependent.
  • #78 antibody does not bind to HEK-293T cells that highly express SDC1, Frizzled 4, TR5A at any concentration, which proves that #78 antibody has a better effect. Specificity, less risk of off-target in patients, and good safety.
  • the present invention uses fully human phage for antibody screening and directly obtains fully human monoclonal antibodies. Compared with traditional hybridoma technology, it saves the difficult steps of mouse antibody humanization, and fully human antibody has lower immunogenicity than humanized mouse antibody, which can be used in antibody drugs or CAR-T applications Have better potential.
  • phage antibodies that can bind to recombinantly expressed CD19 protein and Raji cells at the same time are enriched, and monoclonal antibodies that can specifically bind to the CD19 antigen on the cell membrane surface are selected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/CN2020/091235 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用 Ceased WO2020233589A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP20809306.2A EP3974452A4 (en) 2019-05-20 2020-05-20 Fully human antibody targeting cd19 and application thereof
AU2020277525A AU2020277525A1 (en) 2019-05-20 2020-05-20 Fully human antibody targeting CD19 and application thereof
CN202310120560.XA CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用
JP2022516254A JP7566352B2 (ja) 2019-05-20 2020-05-20 Ｃｄ１９を標的とする完全ヒト抗体およびその応用
US17/613,367 US12516117B2 (en) 2019-05-20 2020-05-20 Fully human antibody targeting CD19 and application thereof
CA3141498A CA3141498C (en) 2019-05-20 2020-05-20 Fully human antibody targeting cd19 and application thereof
CN202080037449.9A CN113840841B (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用
US19/418,243 US20260103517A1 (en) 2019-05-20 2025-12-12 Fully human antibody targeting cd19 and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910419089 2019-05-20
CN201910419089.8 2019-05-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/613,367 A-371-Of-International US12516117B2 (en) 2019-05-20 2020-05-20 Fully human antibody targeting CD19 and application thereof
US19/418,243 Continuation US20260103517A1 (en) 2019-05-20 2025-12-12 Fully human antibody targeting cd19 and application thereof

Publications (2)

Publication Number Publication Date
WO2020233589A1 true WO2020233589A1 (zh) 2020-11-26
WO2020233589A9 WO2020233589A9 (zh) 2021-03-25

Family

ID=73458076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/091235 Ceased WO2020233589A1 (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Country Status (6)

Country Link
US (2) US12516117B2 (https=)
EP (1) EP3974452A4 (https=)
JP (1) JP7566352B2 (https=)
CN (2) CN113840841B (https=)
AU (1) AU2020277525A1 (https=)
WO (1) WO2020233589A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115109140A (zh) * 2022-06-20 2022-09-27 浙江大学医学院附属第一医院 一种靶向特异肿瘤细胞的t细胞受体库构建方法
WO2022257984A1 (zh) * 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用
EP4174093A4 (en) * 2020-06-30 2024-07-31 Nanjing Iaso Biotechnology Co., Ltd. FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING CD19 AND CD22 AND USE THEREOF
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024206897A1 (en) * 2023-03-30 2024-10-03 Cabaletta Bio, Inc. Methods and compositions for treating autoimmune diseases
CN119371540A (zh) * 2024-12-10 2025-01-28 星实(上海)生物医药科技有限公司 抗cd19抗体及其应用
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
US12398187B2 (en) 2019-03-05 2025-08-26 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891108B (zh) * 2022-05-30 2022-11-15 上海驯鹿生物技术有限公司 一种靶向bcma的全人源抗体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233156A (zh) * 2005-06-20 2008-07-30 米德列斯公司 Cd19抗体及其用途
CN101636502A (zh) * 2006-12-13 2010-01-27 梅达雷克斯公司 结合cd19的人类抗体及其用途
CN104558181A (zh) * 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN107531793A (zh) * 2015-10-13 2018-01-02 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774A (zh) * 2018-10-16 2019-02-01 南京医科大学 特异性结合cd19的全人源化抗体及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611814A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2021298707A1 (en) 2020-06-30 2023-02-23 Nanjing IASO Biotechnology Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
WO2022257984A1 (zh) 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233156A (zh) * 2005-06-20 2008-07-30 米德列斯公司 Cd19抗体及其用途
CN101636502A (zh) * 2006-12-13 2010-01-27 梅达雷克斯公司 结合cd19的人类抗体及其用途
CN104558181A (zh) * 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN107531793A (zh) * 2015-10-13 2018-01-02 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774A (zh) * 2018-10-16 2019-02-01 南京医科大学 特异性结合cd19的全人源化抗体及应用

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Phage display-methods and protocols", METHODS IN MOLECULAR BIOLOGY, ISBN: 978-1-4939-7446-7
ALBERT T. GACEREZLBENJAMINE ARELLANO!CHARLES L. SENTMAN: "How chimeric antigen receptor design affects adoptive T cell therapy", CELL PHYSIOL, vol. 231, no. 12, December 2016 (2016-12-01), pages 2590 - 2598, XP055753274, DOI: 10.1002/jcp.25419
CAROLINA BERGERMARY E. FLOWERSEDUS H. WARRENSTANLEY R. RIDDELL: "Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation", BLOOD, vol. 107, no. 6, 10 November 2005 (2005-11-10), pages 2294 - 302
CASTELLA, M. ET AL.: "Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.", MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT., vol. 12, 31 March 2019 (2019-03-31), XP055716791, DOI: 20200729182944A *
DANIEL SOMMERMEYERSTANLEY R. RIDDELL: "Fully human CD19-specific chimeric antigen receptors for T-cell therapy", LEUKEMIA, vol. 31, no. 10, October 2017 (2017-10-01), pages 2191 - 2199, XP055482021, DOI: 10.1038/leu.2017.57
GACEREZ ATHUA CKACKERMAN MESENTMAN CL: "Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression", CANCER IMMUNOL IMMUNOTHER, vol. 67, no. 5, May 2018 (2018-05-01), pages 749 - 759, XP036491811, DOI: 10.1007/s00262-018-2124-1
JIASHENG WANGYONGXIAN HUHE HUANG: "Acute lymphoblastic leukemia relapse after CD 19-targeted chimeric antigen receptor T cell therapy", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 102, December 2017 (2017-12-01), pages 1 - 10
JIEXUASAI-JIIAN CHEN: "Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma", PROC NATL ACAD SCI U S A., 15 April 2019 (2019-04-15)
LAMERS CHGRATAMA JW: "Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells", BLOOD, vol. 117, no. 1, 6 January 2011 (2011-01-06), pages 72 - 82, XP055234814, DOI: 10.1182/blood-2010-07-294520
MARCELA VMAUS ICARL H: "June, Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy", CLIN CANCER RES., vol. 22, no. 8, 15 April 2016 (2016-04-15), pages 1875 - 1884
RYDZEK JHUDECEK M: "tigen Receptor Library Screening Using a Novel NF- B/NFAT Reporter", CELL PLATFORM, MOL THER., vol. 27, no. 2, 6 February 2019 (2019-02-06), pages 287 - 29
SAUNA ZEROSENBERG AS: "Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins", TRENDS BIOTECHNOL, vol. 36, no. 10, October 2018 (2018-10-01), pages 1068 - 1084, XP085480958, DOI: 10.1016/j.tibtech.2018.05.008
See also references of EP3974452A4

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
US12398187B2 (en) 2019-03-05 2025-08-26 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP4174093A4 (en) * 2020-06-30 2024-07-31 Nanjing Iaso Biotechnology Co., Ltd. FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING CD19 AND CD22 AND USE THEREOF
WO2022257984A1 (zh) * 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用
CN115109140A (zh) * 2022-06-20 2022-09-27 浙江大学医学院附属第一医院 一种靶向特异肿瘤细胞的t细胞受体库构建方法
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024206897A1 (en) * 2023-03-30 2024-10-03 Cabaletta Bio, Inc. Methods and compositions for treating autoimmune diseases
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
CN119371540A (zh) * 2024-12-10 2025-01-28 星实(上海)生物医药科技有限公司 抗cd19抗体及其应用

Also Published As

Publication number Publication date
US20220220200A1 (en) 2022-07-14
JP7566352B2 (ja) 2024-10-15
EP3974452A1 (en) 2022-03-30
CN113840841A (zh) 2021-12-24
US20260103517A1 (en) 2026-04-16
CN116589579A (zh) 2023-08-15
JP2022534135A (ja) 2022-07-27
AU2020277525A1 (en) 2022-01-20
WO2020233589A9 (zh) 2021-03-25
US12516117B2 (en) 2026-01-06
EP3974452A4 (en) 2023-08-23
CN113840841B (zh) 2023-03-07
CA3141498A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
CN113840841B (zh) 靶向cd19的全人源抗体及其应用
JP7266117B2 (ja) クローディン１８．２を標的とする抗体又はキメラ抗原受容体
DK2215121T3 (en) ANTI-mesothelin ANTIBODIES AND USES THEREOF
CN111848800B (zh) Pd-l1单结构域抗体及其用途
US10927176B2 (en) Tumor-specific anti-EGFR antibody and application thereof
CN112062851B (zh) 靶向bcma嵌合抗原受体的抗体及其应用
JP2021508246A (ja) 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
JP2020037571A (ja) Ｔｍｃｃ３の阻害による、癌を抑制するための方法
KR20220007120A (ko) 항-cd25 항체 및 이의 적용
CN116640211A (zh) 特异性结合cll1蛋白的单域抗体及其应用
CN112745391B (zh) Pd-l1结合分子
CN116568709A (zh) 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用
TW202413438A (zh) 一種靶向ｐｄ－ｌ１和ｖｅｇｆ的抗體及其應用
CN119176874A (zh) 一种能够结合lilrb2的抗体或其抗原结合片段
CN106084046A (zh) 抗cd3单域抗体
CA3141498C (en) Fully human antibody targeting cd19 and application thereof
HK40072185A (en) Fully human antibody targeting cd19 and application thereof
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
CN117264056A (zh) Nrp-1抗体及其用途
Min The Development of Antibody-Based Therapeutics Against Lymphocyte Antigen 6K (LY6K) for Human Malignancies
TW202413427A (zh) 一種靶向ｐｄ－１和ｖｅｇｆ的抗體及其應用
CN119751675A (zh) 靶向baff-r的全人源抗体及其car-t治疗的应用
성준식 Development and Characterization of Monoclonal Antibody Specific to Oncogenic Variant AIMP2-DX2
WO2021083335A1 (zh) Pd-l1结合分子

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20809306

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022516254

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3141498

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020809306

Country of ref document: EP

Effective date: 20211220

ENP Entry into the national phase

Ref document number: 2020277525

Country of ref document: AU

Date of ref document: 20200520

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 17613367

Country of ref document: US